Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy
Scholar Rock Holding NASDAQ:SRRK surged 12% in extended trading Friday after the Food and Drug Administration approved isembyld, the company’s treatment for spinal muscular atrophy.Isembyld, also known as apitegromab-mstn, was approved for adults and children ages 2 and older who are already receiv…